# Short-Term Linvoseltamab Treatment on Top of Chronic Dupilumab Treatment for Adults With Severe Immunoglobulin E (IgE)-Mediated Food Allergy

> **NCT06369467** · PHASE1 · RECRUITING · sponsor: **Regeneron Pharmaceuticals** · enrollment: 6 (estimated)

## Conditions studied

- Food Allergy

## Interventions

- **DRUG:** linvoseltamab
- **DRUG:** dupilumab

## Key facts

- **NCT ID:** NCT06369467
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-17
- **Primary completion:** 2028-03-28
- **Final completion:** 2028-03-28
- **Target enrollment:** 6 (ESTIMATED)
- **Last updated:** 2026-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06369467

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06369467, "Short-Term Linvoseltamab Treatment on Top of Chronic Dupilumab Treatment for Adults With Severe Immunoglobulin E (IgE)-Mediated Food Allergy". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06369467. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*